Vincera Pharma, Inc.
News
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely
Simply Wall St There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...\n more…
VINC Stock Earnings: Vincerx Pharma Beats EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nVINC stock results show that Vincerx Pharma beat analyst estimates for earnings per share the second quarter of 2024.\nThe post VINC...\n more…
Vincerx Pharma Reports Second Quarter 2024 Financial Results
Globe Newswire Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected...\n more…
Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research Vincerx Pharma, Inc. (VINC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings...\n more…
VINC Stock Earnings: Vincerx Pharma Misses EPS for Q1 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nVINC stock results show that Vincerx Pharma missed analyst estimates for earnings per share the first quarter of 2024.\nThe post VINC...\n more…
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Globe Newswire Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug...\n more…